B-cell translocation gene 2 mediates crosstalk between PI3K/Akt1 and NFκB pathways which enhances transcription of MnSOD by accelerating IκBα degradation in normal and cancer cells by Santhoshkumar Sundaramoorthy et al.
Sundaramoorthy et al. Cell Communication and Signaling 2013, 11:69
http://www.biosignaling.com/content/11/1/69RESEARCH Open AccessB-cell translocation gene 2 mediates crosstalk
between PI3K/Akt1 and NFκB pathways which
enhances transcription of MnSOD by accelerating
IκBα degradation in normal and cancer cells
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Background: B-cell translocation gene 2 (BTG2) belongs to antiproliferative (ARPO) gene family and the expression
of BTG2, human ortholog of rat PC3 and mouse TIS21 gene, has been shown to render cancer cells more sensitive
to doxorubicin treatment by upregulating MnSOD expression without regulating any other reactive oxygen species
(ROS) scavenging enzymes.
Results: In the present study, by employing exogenous and endogenous BTG2/TIS21/Pc3 expression by transfection
and transduction analyses, and by knockdown of gene expression using RNA interference or using gene knockout
cells, we observed that BTG2 increased the binding of activated NF-κB (p65/RelA) to the enhancer element of
MnSOD gene in the 2nd intron, which was regulated by p-Akt1, and the induction of MnSOD by BTG2 was
accompanied with subsequent downregulation of ROS level and cyclin B1 biosynthesis along with the increase of
p21WAF1, resulting in the G2/M arrest independent of p53.
Conclusions: These results show for the first time that BTG2 mediates crosstalk between PI3K-Akt1 and NF-κB
pathways, which regulates p53-independent induction of G2/M phase arrest both in normal and cancer cells.
Keywords: BTG2/TIS21/Pc3 gene, MnSOD, Akt1, NFκB, IκBα, G2/M arrestLay abstract
Background
B-cell translocation gene 2 (BTG2) belongs to the anti-
proliferative gene family, whose expression is dere-
gulated in carcinogenesis of numerous tissues such as
prostate, kidney, breast, liver and brain.Results
Degradation of IκBα was accelerated via activation of
Akt1 in the cells with BTG2 over-expressed, suggesting
the regulation of crosstalk between PI3K/Akt1 and NFκB
pathways.* Correspondence: iklim@ajou.ac.kr
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and Restoration, Ajou University School of Medicine, Suwon 443-721,
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Activated NFκB binds to the enhancer of MnSOD gene
and activates its transcription in the cells with BTG2
expression.
Significance
Learning how BTG2 up-regulates MnSOD is important
for understanding the antioxidant and the tumor sup-
pressive roles of B Cell Translocation Gene 2 in normal
and cancer cells.
Background
Human BTG2 belongs to the antiproliferative (APRO)
gene family along with its orthologs, rat PC3 and mouse
TIS21 [1]. It potentiates NGF-induced differentiation of
PC12 cells and protects neurons from apoptosis [2]. In
contrast, overexpression of BTG2 significantly enhancesd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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http://www.biosignaling.com/content/11/1/69reactive oxygen species (ROS) generation after doxorubi-
cin treatment of HeLa cells via burst of H2O2 by induced
manganese-containing superoxide dismutase (MnSOD)
without regulating catalase and glutathione peroxidase
expression [3]. The APRO gene, including TIS21 [4],
PC3 [5] and BTG2 [6], has originally been reported as a
primary response gene transiently expressed in the es-
tablished cell lines in response to various stimulations,
however, BTG2/TIS21/PC3 (BTG2) expression in mouse
and human tissues has been shown to be rather consti-
tutive [7], and it is found to be significantly reduced dur-
ing carcinogenesis in the epithelial cells of thymus [8],
prostate [9], kidney [10], breast [11], liver [12] and brain
[13]. Furthermore, the loss of BTG2 expression is related
significantly with tumor grade, metastasis and resistance
to cancer treatment, especially in the estrogen receptor
positive breast cancers [14]. In addition, BTG2 regu-
lates cancer cell migration via regulations of ROS level
and chemokines Cxcl3 and Cxcl12 [13,15]. It has been
reported that BTG2 plays a major role at the down-
stream of p53 gene [16], inhibits Ras-induced cell trans-
formation [17] by inhibiting its activation to RasGTP via
direct interaction with Ras protein [18]. Therefore,
BTG2 is also involved in the regulation of mutant p53
activities via inhibiting Ras-related cancer gene signa-
tures [19]. All the above mentioned findings together
strongly suggest the important roles of BTG2 played in
carcinogenesis. BTG2 also regulates both G1/S and G2/
M phase arrest independent of p53 and pRB expression;
G1/S phase arrest is regulated by inhibiting synthesis of
cyclin E and cdk4 activity independent of pRB [20],
whereas BTG2 regulates G1/S progression in pRB
dependent manner by reducing cyclin D1 expression
[21]. Furthermore, BTG2 strongly induces G2/M phase
arrest in U937 myelomonocytic leukemia (p53 null) and
Huh7 (p53 mutant) hepatoma cells [22], therefore, we
earlier suggested BTG2 as a pan-cell cycle inhibitor in-
dependent of p53 and pRB activities via interaction with
Pin1 in response to EGF stimulation [23].
Several reports suggest that BTG2 protein is a general
activator of mRNA deadenylation. BTG2 overexpression
caused accelerated deadenylation of reporters and of
endogenous transcripts. It directly interacts with Caf1
which is a component of the CCR4–NOT deadenylase
complex. These observations for the first time showed
the role of BTG2 in the general control of mRNA decay
[24-26]. As mentioned above, BTG2 enhances MnSOD
expression in HeLa cells after treatment with do-
xorubicin [3] and MnSOD has been suggested as a
new type of tumor suppressor [27]. Overexpression of
MnSOD inhibits the growth of a wide variety of cancer
cells and protects oxygen-utilizing cells from the toxicity
of ROS under physiologic condition [28]. Furthermore,
MnSOD expression is regulated at the transcriptional,translational and posttranslational levels, and Sp1 and
AP-2 are reported to be homeotic transcriptional regula-
tors of MnSOD [29], whereas induction of MnSOD ex-
pression requires the binding of NF-κB transcription
factor (p65) to the enhancer element in the intron-2 of
MnSOD gene [30]. In addition, acetylation of MnSOD
influences its enzymatic activity in response to nutri-
ent status or oxidative stress at the posttranslational
level [31].
In the present study, we attempted to answer the
questions of whether MnSOD can be a direct transcrip-
tional target of BTG2 or not, what is the mechanism of
MnSOD induction by BTG2, what kinds of signal path-
ways regulate the induction of MnSOD expression, and
what is outcome of MnSOD induction by BTG2 in can-
cer and normal cells. In fact, various lines of evidences
suggest that free radical-scavenging agents inhibit neo-
plastic processes at the cellular and molecular levels
[32]. Tumor cells are low in MnSOD activity and its ex-
pression, compared to normal counterparts [27], there-
fore, tumor cells may particularly be able to accumulate
higher levels of superoxide or hydrogen peroxide than
the normal, which may enhance survival and prolifera-
tion of the cancer cells. We observed in the present
study that the expression of MnSOD was upregulated by
BTG2 at the transcription level via degradation of IκBα
in cancer and normal cells, and that underlying mecha-
nism of APRO effect of BTG2 involved the crosstalk bet-
ween PI3K-Akt1 and NFκB pathways, which resulted in
the scavenge of ROS and increased p21WAF1 expression.
Results
BTG2 upregulates MnSOD expression in HeLa cells
We earlier showed that BTG2 sensitizes HeLa cells
to doxorubicin treatment via induction of endogenous
MnSOD expression [3]. To investigate molecular me-
chanism involved in MnSOD induction by BTG2, we
overexpressed BTG2 gene in HeLa cells by DNA trans-
fection and viral transduction, and found that BTG2
upregulated MnSOD expression in the dose-dependent
manner both in its mRNA (Figure 1A and 1C) and pro-
tein (Figure 1B) levels. On the other hand, endogenous
level of MnSOD expression in the TIS21−/− MEF along
with wt-MEF was much lower in the TIS21−/− MEF than
the control (Figure 1D), suggesting that the effect of
BTG2 on MnSOD expression was both endogenously
and exogenously regulated in mouse fibroblasts and can-
cer cells, and that there is a possibility of MnSOD gene
as a direct target of BTG2.
BTG2 activates NFκB-response element of MnSOD gene in
the 2nd intron
To investigate a mechanism of MnSOD induction by
BTG2 in HeLa cells, we performed luciferase assay using
C RT-PCR analysis
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Transfection
Figure 1 Upregulation of MnSOD expression in HeLa cells by BTG2/TIS21. (A) Transfection analysis; HeLa cells (2×105 cells in 60 mm) were
transfected with pcDNA3-TIS21(HA) for 6 h along with the empty vector (pcDNA3-HA) to adjust total DNA contents, and then subjected to RT-
PCR analyses using the primers described in the Additional file 5. Expression of MnSOD was increased in the BTG2 overexpressed samples in a
concentration dependent manner. GAPDH was employed as a control expression of transcription. (B) Expression of MnSOD was increased along
with the overexpression of BTG2/TIS21, examined by immunoblot analysis. Tubulin expression was used for loading control in each lane. (C)
Transduction analysis; Ad-BTG2 was infected to HeLa cells (2 × 105 in 60 mm dish) for 5 h and then BTG2-mediated MnSOD expression was
evaluated by RT-PCR. Expression of MnSOD was increased after Ad-BTG2 transduction. (D) To evaluate effect of endogenous BTG2/TIS21 gene on
the expression of MnSOD, wild type-MEF and BTG2/TIS21 knockout-MEF lysates were subjected to immunoblot analysis. Endogenous level of
MnSOD expression was lower in the TIS21−/−MEF than the wt-MEF, when measured by Image J software.
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gene ligated to the upstream of luciferase, however, there
was no difference in the promoter activity by the expres-
sion of BTG2 gene (Figure 2A), except by Sp1, the posi-
tive control. Since inducible expression of MnSOD has
been shown to be regulated by NFκB binding to the en-
hancer element of MnSOD gene [30], we subcloned the
NF-κB response element (κB-RE) into the pGL3-BASIC
vector and performed luciferase analysis with or without
BTG2 coexpression. As shown in Figure 2B, the lucifer-
ase activity was increased with BTG2 coexpression,
suggesting that BTG2 enhances the activity of κB-RE in
the MnSOD gene. Proteins of the transfected genes were
monitored by immunoblot analyses and presented under
the Figure 2A and 2B. To rule out other possibility of
MnSOD induction by BTG2 expression, the activity of
FOXO3a, a well known transcription factor of MnSOD
in quiescent cells against oxidative stress [33], was ana-
lyzed by measuring its phosphorylation on serine253
residue, however, there was no significant difference of
its activity after BTG2 expression (Additional file 1:
Figure S1A). To further investigate the BTG2-mediated
activation of κB-RE of MnSOD gene, the activation of
NFκB pathway in HeLa cells was evaluated by measuring
the degradation of IκBα in proteasome [34]. Increasingamounts of BTG2 expression significantly enhanced the
degradation of IκBα protein along with MnSOD expres-
sion (Figure 2C). Moreover, when the cells were treated
with MG132 to block ubiquitin proteasome pathway,
BTG2-mediated MnSOD induction was accordingly re-
duced (Figure 2D). The data support our observation in
Figure 2B that BTG2 increased transcription of MnSOD
through the activation of κB-RE. To further confirm the
activation of NFκB by BTG2, we performed ChIP ana-
lysis using the cell lysates obtained from the BTG2 and
the LacZ expressers. As expected, the interaction of p65
with κB-RE was observed only in the BTG2 expresser,
but not in the control (Figure 2E, lower panel). Since
TPA has been known to induce MnSOD through NFκB
pathway [35,36], TPA treatment (100 ng/mL for 2 h)
was employed as a positive control for the ChIP analysis.
As expected, TPA increased IKBα degradation (Additional
file 1: Figure S1B) and induced binding of p65 to κB-RE of
MnSOD gene (Figure 2E, upper panel). To further eval-
uate the upstream kinase of IκBα, phosphorylation of
IKKα/β on serine176 residue was examined, and its mi-
nimal activation was observed along with significant deg-
radation of IκBα in the BTG2 expresser without any other
antioxidant scavenging enzymes such as catalase, GPX, or
SOD1 (Figure 2F).
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Figure 2 Activation of NFκB-response element in the 2nd intron of MnSOD gene by BTG2. (A) MnSOD promoter analysis; Cells (0.5×105/12
wells) were cotransfected with BTG2 cDNA and promoter DNA of MnSOD gene and then subjected to luciferase analysis. Transfection of BTG2 up
to 100 ng failed to activate promoter of MnSOD. Sp1 cDNA was employed as a positive control. Lower panel shows protein expressions of the
transfected DNAs and loading control. (B) Cells were cotransfected with BTG2 cDNA and the κB-RE before luciferase assay. Expression of MnSOD
was significantly increased with transfection of BTG2, indicating the activation of κB-RE by BTG2. Immunoblot analysis shows protein expression
of BTG2-HA and loading control. (C) To further investigate the regulation of NFκB activation and MnSOD induction by BTG2 expression, IκBα
degradation was examined by immunoblot analysis. Note the degradation of IκBα and MnSOD expression in the BTG2-dependent manner.
(D) Transduction of HeLa cells with Ad-BTG2 was performed and then treated with 10 μM of MG132 for 1 h before RT-PCR analysis. MG132
abolished induction of MnSOD expression by BTG2, suggesting the upregulation of MnSOD expression by BTG2 via proteasomal degradation of
IκBα. (E) Cell lysates with the LacZ or the BTG2 expressers were subjected to ChIP analysis with anti-p65 antibody, and then the interaction was
verified by PCR reaction with the primers written in the Additional file 5. To verify our analysis, HeLa cells were treated with or without 100 ng of
12-O-tetradecanoylphorbol-13-acetate (TPA) for 2 h and then applied to ChIP assay as a positive and negative control. Unstimulated IgG was
employed to exclude the nonspecific interaction. Inputs indicate total amount of κB-RE present in the samples. Note the interactions of p65 with
κB-RE only in the BTG2 expressers and the TPA treated positive cells. (F) Immunoblot analyses showing the activation of IKKα/β in the BTG2
overexpressers without any changes in the expression of other anti-oxidant enzymes.
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degradation
To further confirm the specificity of BTG2 effect on
MnSOD expression via NFκB activation, HeLa cells were
transfected with short interfering RNAs against BTG2
(siBTG2), and the changes of MnSOD and IκBα expres-
sion were evaluated by RT-PCR and immunoblot analyses,
respectively. Knockdown of endogenous BTG2 downre-
gulated MnSOD level (Figure 3A), whereas IκBα was fur-
ther accumulated (Figure 3B). Moreover, transfection ofsiCont (nM)
siBTG2 (nM)
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Figure 3 Regulation of BTG2 mediated–NFκB activation by IκBα degr
and its regulation of MnSOD induction, the mixture of five short interfering
48 h and then expression of MnSOD was analyzed by RT-PCR. The expressi
indicating the regulation of MnSOD expression by endogenous BTG2. The
the Additional file 6. (B) Immunoblot analysis revealing the regulation of Iκ
by transfection of HeLa cells with 100 nM siBTG2 abolished BTG2 protein e
siBTG2 blocked the effect of exogenous BTG2/TIS21 on IκBα degradation, ind
endogenous BTG2 genes on the regulation of NFκB activation. (D) To furth
the upregulation of MnSOD expression, HeLa cells were infected with lenti
Overexpression of the mutant reduced upregulation of MnSOD transcriptio
degradation of IκBα mutant (Ser32, 36Ala), examined by immunoblot analyssiBTG2 also reduced the effect of exogenous BTG2 on the
degradation of IκBα protein in the cells (Figure 3C). To
confirm the effect of IκBα degradation on the BTG2-
regulated MnSOD induction, successive transductions of
the lentivirus with nondegradable IκBα mutant and the
Ad-BTG2-HA were performed. As shown in Figure 3D,
the BTG2-induced MnSOD expression was reduced by
coinfection with IκBα-mutant which was unable to be
disrupted (Figure 3E), supporting the activation of NFκB
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adation. (A) To confirm the effect of BTG2 on the activation of NFκB
RNAs to BTG2 (siBTG2#1 - siBTG2#5) was transfected to HeLa cells for
on was downregulated by the concentration of siBTG2 dependently,
sense and the antisense primer sequences of siBTG2 were described in
Bα degradation by BTG2. Knockdown of endogenous BTG2 expression
xpression, in contrast to the accumulation of IκBα. (C) Transfection of
icating the same effect of the exogenous BTG2/TIS21 and the
er evaluate the effect of BTG2/TIS21 gene on the IκBα degradation and
virus containing IκBα mutant (Ser32, 36Ala) prepared in our laboratory.
n stimulated by BTG2 gene. (E) Complete failure of the BTG2-mediated
is.
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We have earlier shown that the activation of Akt in
response to estradiol requires BTG2 expression in MEF
and bone marrow precursor cells (Lin--c-Kit+-Sca1+) [37].
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Figure 4 Regulation of BTG2-enhanced IκBα degradation via activatio
of the IκBα degradation by BTG2 were investigated. (A) Immunoblot analys
the BTG2 expresser. To explore whether there is a crosstalk between PI3K a
PI3K inhibitors, LY294002 (B) and Wortmanin (C), respectively, and then reg
Note significant inhibition of BTG2-mediated IκBα degradation after treatm
and NFκB pathways by the expression of BTG2. (D) RT-PCR revealing the sp
Akt1. (E) BTG2-mediated IκBα degradation was significantly inhibited by tra
IκBα degradation at all, supporting the specific effect of Akt1 on the activa
of Akt1 on the BTG2-mediated IκBα degradation, transfection of siAkt1 RNA
analysis was performed with anti-p65 antibody. As expected, interaction of
coexpressers (1.9 vs. LacZ and siControl) than that of the BTG2 alone expre
activation by siAkt1 (over 40%) and the activity of Akt1 at the upstream of
binding to κB-RE after transfection of siAkt1 was quantified by Image J soft
on those of the Input (ChIP/Input) were showed below the Figure 4F. Theand NFκB pathways was explored. When HeLa cells were
transfected with BTG2, Akt phosphorylation on Serine473
was significantly increased (Figure 4A). To further explore
the crosstalk between pAkt and IκBα degradation, PI3K
inhibitors (LY294002 and Wortmanin) were applied to theVector-HA (0.8µg)
BTG2-HA (0.8µg)
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n of PI3K-Akt1. Based on our previous report [37], upstream signals
is showing the significant phosphorylation of Akt at Ser473 residue in
nd NFkB pathways, HeLa cells transfected with BTG2 were treated with
ulation of IκBα degradation was examined by immunoblot analyses.
ent with PI3K inhibitors, suggesting the cross-talk between PI3K-Akt
ecific knockdown of Akt1, not Akt2, by the short interfering RNAs to
nsfection of siAkt1, whereas transfection of siControl failed to change
tion of BTG2-mediated NFκB pathway. (F) To further specify the effect
was combined with Ad-BTG2 infection in HeLa cells, and then ChIP
p65 with κB-RE was significantly reduced in the BTG2 and siAkt1
sser (3.3 vs. LacZ and siControl), indicating downregulation of NFκB
NFkB activation in the presence of BTG2 expression. Inhibition of p65
ware, and the relative densities of kB-RE found in the ChIP assay based
experiment was repeated (n = 3).
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http://www.biosignaling.com/content/11/1/69test system and the effect of PI3K inactivation on the ex-
pression of IκBα and Akt activation was examined. The
result in the 3rd and 4th lanes in Figure 4B and 4C clearly
showed the regulation of NFκB activation by PI3K-Akt
signal. To further specify the role of Akt1 in the activation
of NFκB pathway, HeLa cells were transfected with siAkt1
(Figure 4D) and the inhibition of BTG2-mediated IκBα
degradation was examined by immunoblot analysis. As
expected, knockdown of Akt1 recovered BTG2-mediated
degradation of IκBα expression in the siAkt1 and BTG2
cotransfected cells (Figure 4E). Moreover, ChIP assay
revealed inhibition of p65 binding to κB-RE up to
40% by cotransfection of siAkt1 and BTG2 (3rd and
4th lanes in Figure 4F). These data strongly suggest
the BTG2-mediated Akt1 activation at the upstream
of IκBα degradation.
To exclude the possibility that the crosstalk is a
phenomenon limited to HeLa cells, A549 human lung
cancer cells were employed and confirmed the induction
of MnSOD by transfection of BTG2 (Figure 5A) with
concomitant degradation of IκBα (Figure 5B). Moreover,
the specific binding of p65 to κB-RE was also observed
in the BTG2 expressers by ChIP assay (Figure 5C). At
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Figure 5 BTG2-mediated MnSOD expression via crosstalk of Akt1 and
expression by BTG2 via activations of Akt1 and NFκB pathways in addition
transfection of BTG2/TIS21 and adenoviral transduction analyses for the follo
expression of MnSOD gene in A549 cells after overexpression of BTG2. (B)
transcfection of BTG2 for 48 h. (C) ChIP assay revealing the interaction of p
(D) Activation of NFκB pathway by Akt1 in the BTG2 transfected A549 cells
transfection of siAtk1 to A549 cells for 48 h.was confirmed by employing knockdown of Akt1 in the
same cells (Figure 5D). Furthermore, BTG2 mediated-
IκBα degradation was confirmed also in MCF7 breast
cancer cells and wt-MEF after transfections of BTG2
cDNAs and siBTG2/TIS21, respectively (Additional file 2:
Figure S2). All these data strongly suggest the regulation
loop between BTG2-PI3K/Akt1-NFκB pathways for the
induction of MnSOD expression.
BTG2 enhances G2/M arrest along with reduction
of H2O2 level
To explore physiologic significance of BTG2 overex-
pression, HeLa cells were synchronized at the late G1
and early S phases by thymidine double blocks and the
cell cycle progression was monitored for 12 h by FACS
analysis after the release. Figures 6A (X-axis corresponds
to DNA content and Y-axis represents number of event)
and 6C revealed that the expression of cyclin B1 was de-
layed along with G2/M arrest in the BTG2 expressers at
4 h after the release and the phenomenon is well accord-
ant with our previous report observed in U937 cells [22].
When the percentage of cells in G1 and G2 phases were
calculated using the ModFit software, Figure 6B clearly
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Figure 6 (See legend on next page.)
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Figure 6 G2/M arrest along with reduction of H2O2 level in the BTG2 expresser. HeLa cells were synchronized at G1/ S boundary by
thymidine double block (TDB) before the following experiments. (A) Cell cycle analysis; Cells were harvested at the indicated times after TDB for
FACS analyses. The X-axis corresponds to DNA content and Y-axis indicates number of cells. Note significant G2/M arrest in the BTG2 expresser at
8 h compared with the LacZ. (B) The cells in each phase were analyzed by ModFit software, and the statistical difference between the LacZ and
the BTG2 expressers were evaluated by paired t-test. Note statistical significance in the G1 phase (p = 0.04) and the G2/M phase (p = 0.03) cells in
the BTG2 expresser compared to LacZ control at 8 h. (C) Immunoblot analysis; Delayed synthesis of cyclin B1 in the BTG2 overexpresser at 4 h
after TDB. (D) RT-PCR analysis showing the increased expressions of MnSOD and p21WAF1 in the BTG2 overexpresser at 6 h and at 8 h after TDB,
respectively. (E) Induction of p21WAF1 expression in HeLa cells overexpressing BTG2 gene, proved by transfection and transduction of BTG2 gene.
(F) Reduction of intracellular H2O2 in the BTG2 overexpresser than the LacZ control. HeLa cells were treated with 20 μM DCFDA for 15 min and
analyzed by FACS. Note significant reduction of H2O2 level in the BTG2
/TIS21 expresser than the LacZ control at 7 h after TDB.
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G2/M arrest in the BTG2 expresser is restricted only to
cancer cells or not, we analyzed cell cycle progression of
NIH3T3 cells infected with adenovirus carrying either
BTG2 or LacZ control and synchronized at G1/S phases
by using thymidine double block (Additional file 3:
Figure S3A). There was no significant differences of
G2/M phase progression and cyclin B1 expression in
the NIH3T3 cells (Additional file 3: Figures S3B-S3D),
suggesting that induction of G2/M arrest by BTG2
overexpression might be limited to cancer cells which
usually contain a defect in G1/S checkpoint, BTG2-
mediated MnSOD induction was preceded to p21WAF1
expression (Figure 6D) and the expression of p21WAF1
was evident both in the RNA and protein levels
(Figure 6E and Additional file 4: Figure S4) after
transduction and transfection of BTG2 gene in HeLa
cells. Furthermore, BTG2 expresser scavenged intra-
cellular H2O2 level along with cell cycle progression
from G1/S to G2/M phase (Figure 6F). All the results
can be supported by the notion that NFκB enhances
G2/M arrest via induction of p21WAF1 [38].
Discussion
In the present study, we presented evidences on the
crosstalk between PI3K-Akt and NFκB pathways after
ectopic and endogenous BTG2 expressions in normal
and cancer cells via activation of Akt1 and degradation
of IκBα protein. The signals regulating MnSOD ex-
pression - the binding of NFκB (p65) to the enhancer
element of MnSOD gene in response to BTG2 ex-
pression - significantly reduced ROS level and cyclin B1
biosynthesis as opposed to p21WAF1 induction, which
resulted in G2/M arrest (Figure 7). It has been known
that the homeotic expression of MnSOD is regulated by
AP-2 and SP-1 binding to the promoter of MnSOD gene
[29], whereas induced expression of MnSOD requires
enhancer activation located in the 2nd intron [30]. In-
deed, the upregulation of BTG2-enhanced MnSOD ex-
pression might be one of the intracellular cooperation
between APRO gene and a tumor suppressor through
the regulations of cell division cycle and intracellular
ROS level, since the notion was supported by luciferaseassays using promoter and enhancer element of MnSOD
gene and by reverse correlations of IκBα and MnSOD
expression, in addition to ChIP and immunoblot ana-
lyses (Figure 2). Specificity of the effects was further
confirmed by RNA interference and IκBα (Ser32, Ser36
to Ala32, Ala36) mutant analysis in HeLa cells (Figure 3)
and A549 cells (Figure 5) in addition to the wt-MEF and
MCF 7 breast cancer cells (Additional file 2: Figure S2).
Our present results are well supported by a recent study
that BTG2 works as a coactivator of the antioxidant
transcription factor, NFE2L2, which induces antioxidant
gene expression including catalase and superoxide dis-
mutases 1 and 2, thus BTG2 is able to protect human
mammary epithelial cells from oxidative stress by H2O2
and other oxidants [39]. In contrast to our present re-
sult, HeLa cells have been shown to enhance cell death
by H2O2 burst along with MnSOD induction when the
cells are exposed to toxic dose (1.0 μg/ml) of doxoru-
bicin [3]. Therefore, it is highly likely that the BTG2-
mediated induction of MnSOD destines cell fate to
either G2 arrest or cell death depending on the cellular
context. Accordingly, the present study highlights the
role of BTG2 as a regulator of ROS level by MnSOD in-
duced via NFκB activation.
BTG2-mediated activation of NFκB via PI3K-Akt path-
way was independent of p53 status in normal and cancer
cells (Figures 4 and 5, and Additional file 2: Figure S2)
such as HeLa (p53 low expresser due to HPV E6 & E7
gene expression), A549, wt-MEF and MCF7 cells (wt-p53),
therefore, BTG2-regulated crosstalk between PI3K-Akt1
and NFκB pathways was active in a p53-independent
manner. Recently, there are several published reports on
the crosstalk; in the growth and survival of primary effu-
sion lymphoma cells [40], malignant invasion and me-
tastasis of NSCLC cells [41], and antiproliferative and
proapoptotic effects of metformin in various tumor cells
[42]. In addition, DHEA-induced proliferation of ventral
prostate epithelial cells and T-cell activation are also finely
tuned by NFκB activation via PI3K-Akt [43,44]. However,
the above reports did not identify any specific transducer
between PI3K-Akt1 and NFκB pathways, whereas we
presented here BTG2 as a signal mediator between
























Figure 7 Crosstalk between PI3K-Akt and NFκB pathways after BTG2 expression in normal and cancer cells via activation of Akt1 and
degradation of IκBα protein. The endogenous and exogenous expressions of BTG2/TIS21 significantly induces IκBα degradation via Atk1
activation in cancer and normal cells. The activated NFκB (p65) binds to the enhancer element on the 2nd intron, not promoter, of MnSOD gene
and upregulates its transcription in response to BTG2/TIS21 expression. The induction of MnSOD expression triggers scavenge of ROS level and the
BTG2-mediated ROS reduction inhibits cell cycle progression at G2 phase entry via inhibition of cyclin B1 biosynthesis in contrast to the
upregulation of p21WAF1 expression.
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to be characterized.
The endogenous expression and activity of MnSOD
are significantly downregulated in various cancer cells
and tumor tissues as compared with counterpart normal
cells [45]. Many studies showed that deficiency of the
enzyme activity might be due to the reduction of its
transcription. In the present study, we presented for the
first time precise signal pathways of MnSOD upre-
gulation by BTG2, in addition to transcriptional regu-
lation of MnSOD expression by enhancer activation of
the gene in a BTG2-concentration dependant manner
(Figure 1), clearly confirming the involvement of BTG2
in the regulation of MnSOD activity in vivo. In the syn-
chronized HeLa cells, BTG2 downregulated cyclin B1
biosynthesis along with G2/M arrest (Figure 6A-6C).
The phenomenon is well accordant with our previousreport on the disruption of cyclin B1-FoxM1 regulation
loop by BTG2 [12]. In addition, sequential inductions of
MnSOD and p21WAF1 expressions (Figure 6D and 6E)
can also be supported by the notion that NFκB enhances
G2/M arrest via induction of p21WAF1 [38]. Even though
p21WAF1 is a p53 downstream gene, it is also regulated
in the p53-independent manner by NFκB activation
when the cells are treated with doxorubicin [46], more-
over, upstream promoter of p21WAF1 contains NFκB re-
sponse elements [47], supporting that NFκB has been
considered as a transcription factor for p21WAF1 in-
dependent of p53. Fortuitously, all the available data
indicate the BTG2-mediated NFκB activation via its
interaction with κB-RE and subsequent upregulation of
p21WAF1 in the p53 nonfunctioning cancer cells.
Depending on the level of ROS, cellular responses
are quite variable, ranging from transient to permanent
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of changes observed in the synchronized HeLa cells
(Figure 6), e.g. delayed biosynthesis of cyclin B1 along
with delayed entry into G2 phase at 4 h, increase of
MnSOD expression at 6 h, significant reduction of
H2O2 level at 7 h, and then p21
WAF1 induction and
G2/M phase arrest at 8 h after the release from thymi-
dine double blocks reflect a mechanism of APRO ac-
tivity exhibited by BTG2. Nonetheless, cellular response
to BTG2 expression would be diverse, depending on the
cellular context and its ROS level.
Conclusions
It is well documented that cancer cells contain defective
mitochondria and often reprogram their metabolic path-
ways to meet with their energy requirements during the
process of tumor progression [48]. The major metabolic
phenotype described in Warburg effect is the shift of
ATP generation from oxidative phosphorylation to gly-
colysis under physiologic oxygen concentration [49].
Here, MnSOD plays a critical role in the maintenance of
mitochondrial integrity, because cells lacking MnSOD
are defective in ATP generation by impairing oxidative
phosphorylation. Therefore, MnSOD has been regarded
as a guardian of powerhouse in tumorigenesis models
[50]. Low level of MnSOD may create threat to mito-
chondrial function at the early stages of carcinogenesis
[51], therefore, cancer cells contain defective mitochon-
dria due to lower expression of MnSOD. In that sense, it
is worth to note that BTG2-induced MnSOD expression
might be one of the early events of tumor suppression
by maintaining the integrity of mitochondria. We have
recently observed that exogenously expressed BTG2 was
rapidly translocated to mitochondria in response to
H2O2 in H9c2 cardiomyoblasts [52]. Therefore, we spe-
culate that BTG2 might play a significant role in the
modulation of mitochondrial defect in cancer cells. In
vivo studies using BTG2 knockout mice might be helpful
in finding the significance of BTG2 in carcinogenesis.
Materials and methods
Cell treatment reagents and plasmids
HeLa cells were cultured in DMEM medium supple-
mented with 10% heat inactivated fetal bovine serum
(FBS) in a humidified atmosphere containing 5% CO2 at
37°C. Wild type mouse embryo fibroblast (MEF) were
prepared in our laboratory with 13.5 day old embryos
isolated from wild type and BTG2/TIS21-/- mice, and then
cultured in DMEM with 10% FBS. Antibodies against
α-tubulin, hemagglutinin (HA), IκBα, pIKKα/β-Ser176,
pAkt, cyclinB1, p21WAF1 and BTG2 were purchased
from Santa Cruz (Santa Cruz, CA), glutathione peroxid-
ase (GPX), SOD1, MnSOD and catalase were from the
Lab Frontier (Lab Frontier Life Science Institute, Seoul,Korea), Akt2 was from Upstate Biotechnology (Lake
Placid, NY), and Akt, pFoxO3a-Ser253 and BCL-xL
were purchased from Cell Signaling Technology Inc.
(Danvers, MA). Anti β-actin antibody, LY294002, cy-
cloheximide, Wortmanin and MG-132 were purchased
from Sigma (St. Louis, MO). Cell treatment times and
concentrations were mentioned in legends for figures.
The BTG2/TIS21 were inserted into the EcoRI and XhoI
sites of the pcDNA3-HA vector. DNA sequences of
BTG2/TIS21 in pcDNA3-HA were verified by automatic se-
quence analysis (ABI 377). Full-length SP1 were cloned
into the EcoRI and SalI sites of p3xFLAG-CMV (Sigma).
Adenoviral transduction of HeLa cells with BTG2 gene
Ad-BTG2 virus was prepared in our laboratory according
to the method described previously [3,12,32] and in-
fected to HeLa cells for 5 h, and then incubated in the
complete media for 48 h until subjected to various ana-
lyses. Infection of Ad-LacZ was employed as the control
of adenoviral transduction.
Cloning of κB-response element (κB-RE) into pGL3
basic vector
Cloning of enhancer element of MnSOD gene was
performed in our laboratory by PCR amplification using
human genomic DNAs isolated from HeLa cells as the
template, and the upstream and downstream primers
were obtained from the 2nd intron of MnSOD gene, 5′
ACCTCGAGTGATTGTGTTTGAAGTAAATG-3′ and
5′ AAAAAGCTTTGATTCCACAAGTAAAGG-3′, re-
spectively. PCR amplification was performed using pfu
polymerase (Takara Inc., Japan) according to the proto-
col; Denaturation at 95°C for 30s, annealing at 55°C for
30s, and elongation at 72°C for 60s. The amplified PCR
products were digested with XhoI and HindIII, and then
subcloned into pGL3 basic luciferase reporter vector
purchased from Promega (Madison, WI) using the same
sites. The recombinant DNA sequences, κB-RE, were
confirmed by nucleotide sequencing (Genotech Corp.,
Daejeon, Korea).
Transfection analyses
Increasing amounts of BTG2/TIS21 cDNAs were co-
transfected with either promoter construct or κB-RE of
MnSOD gene using Metafectane reagent (BionTex,
Munich, Germany) and thymidine kinase promoter-
driven Renilla luciferase plasmid as a control DNA. The
activity of luciferase was measured by TD 20/20 lumi-
nometer (Turner BioSystems, Sunnyvale, CA) according
to the instructions for the Dual-Luciferase Reporter
Assay System (Promega, Madison, WI). All transfection
experiments and luciferase assays were carried out in trip-
licate and repeated more than twice. Reporter construct
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from Dr. Curtis Harris in NIH, USA.Chromatin immunoprecipitation (ChIP) assay
Binding of activated NFκB to the κB-RE was analyzed
by ChIP assay. Cells fixed with 1% formaldehyde were
washed twice using ice-cold PBS containing protease
inhibitors (1.0 mM PMSF, 1.0 μg/ml aprotinin, and
1.0 μg/ml pepstatin), and the cell pellets collected by
centrifugation at 5,000 × g for 5 min at 4°C were
resuspended in the lysis buffer (50 mM Tris–HCl, pH
8.1, 10 mM EDTA, and 1.0% SDS) containing protease
inhibitors. Cross-linked chromatin was sonicated on ice
to shear DNA to 200 to 1000 bp length and then
centrifuged at 13,000 × g for 10 min to remove cell deb-
ris. The soluble chromatin was then diluted 10-fold in
ChIP dilution buffer (16.7 mM Tris, 167 mM NaCl, 1.1%
Triton X-100, and 0.01% SDS). The diluted soluble
chromatin fraction was pre-cleaned by 30 μl protein G-
agarose beads. Pre-cleaned chromatin was mixed with
the anti-p65 antibody (ChIP grade, Santa Cruz) over-
night at 4°C. Parallel control experiments were also
performed with pre-immune control precipitates using
unstimulated IgG. The antibody-chromatin complex was
pulled-down with protein G beads for 2 h rotation at
4°C. Protein G beads were then washed by rotation at
4°C with 400 μl of buffer in the following order; low salt
immune complex wash buffer (20 mM Tris–HCl, pH
8.1, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 1%
SDS), high salt immune complex wash buffer (20 mM
Tris–HCl, pH 8.1, 500 mM NaCl, 2 mM EDTA, 1.0%
Triton X-100, 1.0% SDS), LiCl immune complex wash
buffer (10 mM Tris–HCl, pH 8.1, 0.25 mM LiCl, 1.0%
deoxycholate, 1.0% Nonidet P-40, 0.1% SDS), followed
by two washes with 10 mM Tris–HCl, pH 8.1 with
1.0 mM EDTA, pH 8.1. Precipitated immune complexes
were eluted twice with 250 μl of elution buffer (1.0%
SDS, 0.1 M NaHCO3) at room temperature for 15 min
each. Reversal of cross-linking was performed by adding
20 μl of 5 M NaCl to the elution mixture and heating at
65°C overnight. The elutes were mixed with 0.5 M
EDTA, 1.0 M Tris (pH 6.5) and 2 μl of 10 mg Proteinase
K and shaken well. DNAs recovered by phenol:chloro-
form extraction and ethanol precipitation were resus-
pended in nuclease-free water for PCR amplification
using the primers described in the Additional file 5.Measurement of the level of reactive oxygen species
The intracellular H2O2 concentration was measured by
FACS analysis using 20 μM 2′,7′-dichlorodihydrofluo-
rescein diacetate (H2-DCFDA, Molecular Probes). Cells
infected with Ad-BTG2 or Ad-LacZ were pretreated
with H2-DCFDA for 10 min and then the fluorescenceof dichlorodihydrofluorescein derived from oxidation of
H2-DCFDA was measured.
Small interfering RNAs (siRNAs) and preparation of
lentivirus with IκBα mutant
The five sets of siBTG2 sequences and one set of siAtk1
used in the experiments are described in the Additional
file 6. The mixture containing siRNAs was prepared with
a concentration of 4 μM each and used for transfection
of normal and cancer cells using Lipofectamine 2000
(Invitrogen, Carlsbad, CA) according to the manufac-
turer’s instruction. Lentivirus with IκBα-mutant was pre-
pared in 293 T cells by cotransfection of IκBα-mutant
(Ser32, Ser36 to Ala32, Ala36) and pCMV-VSV-G helper
constructs using Lipofectamine 2000. Viral supernatants
were harvested in 48 h and filtered through a 0.22 μm
filter (Millipore). HeLa cells (2 × 105/60 mm-diameter)
were transduced with 250 μl of the supernatant. Culture
medium was changed in 12 h and maintained for 2 days
until analysis.
RT-PCR
Total cellular RNAs (1.0 μg) isolated with RNAiso Plus
were used for cDNA preparation and then amplified by
PCR kit (Takara Inc., Japan); First strand cDNA was syn-
thesized using oligo-dT by reverse transcription reaction
in 10 μl of reaction volume. The gene of interest was
amplified by ExTaq polymerase in PCR kits using primer
sequences described in the Additional file 5.
Immunoblot analyses
Cells were sonicated with RIPA buffer [50 mM Tris/
HCl, pH 7.5, 150 mM NaCl, 1.0% Nonidet P-40, 0.1%
SDS, 0.5% deoxycholic acid, 50 mM sodium fluoride,
1.0 mM sodium vanadate, 1.0 mM phenylmethylsulfonyl
fluoride (PMSF), 1.0 μg/ml leupeptin], and 40 μg of cell
lysates were resolved on 8 to 12% SDS-PAGE in 25 mM
Tris-glycine buffer. The gel-resolved proteins were then
transferred to nitrocellulose membrane. The membranes
were blocked with 5% nonfat skim milk in PBS con-
taining 0.05% Tween 20 (PBST) for 1 h and then in-
cubated with respective antibodies overnight at 4°C.
Nitrocellulose membranes were washed three times with
PBST and then incubated with horseradish peroxidase-
conjugated secondary antibodies for 1 h. ECL (Amersham
Biosciences, UK) kit was employed to visualize protein ex-
pression levels. Protein bands were quantified by relative
optical densities using Image J software.
Cell synchronization and FACS analysis
HeLa cells were synchronized with 1.0 mM thymidine
treatment for 20 h, released for 9 h and then treated
again with thymidine for 13 h more before release from
the treatment. In the meantime, cells were infected with
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rimental time points are further explained in detail in
the Additional file 3: Figure S3A. Cell cycle analysis
was performed by flow cytometry (BD FACScan II,
BD Biosciences, San Jose, CA) after staining the DNA
content with propidium iodide (Sigma) according to
the manufacturer’s instruction. Cell cycle phases were
analyzed by ModFit software.
Additional files
Additional file 1: Figure S1. (A) HeLa cells (2 × 105) were seeded in
60 mm dish and maintained for 12 h. Transfection of the cells with BTG2-
HA (0.8 μg of DNA) or control vector (0.8 μg of DNA) was performed for
6 h, and followed by media change. In 48 h, cells were harvested for
immunoblot analysis using anti-pFOXO3a antibody. α -tubulin was used
as a loading control. (B) HeLa cells were treated with TPA 100 ng for 2 h
and analyzed for IκBα degradation.
Additional file 2: Figure S2. (A) MCF7 cells (2 × 105) were seeded in
60 mm dish and maintained for 12 h, and then subjected to transfection
for 6 h with BTG2 cDNA (0 ~ 0.8 μg) until media change. Equal DNA
content was adjusted with the control vector. In 48 h, cells were
harvested for immunoblot analysis and examined the degradation of
IκBα by transfection of BTG2. (B) ChIP assay; the above treatment
revealed specific interaction of p65 to kB-RE only in the BTG2 expressers.
(C) To confirm the effect of BTG2 expression on IκBα degradation not
only in cancer cells but also in normal cells, wild type mouse embryo
fibroblasts (MEF) were transfected with siBTG2 (~100 nM), and then
accumulation of IκBα was examined by immunoblot analysis along with
knockdown of BTG2 expression by RT-PCR.
Additional file 3: Figure S3. (A) Schema of cell synchronization at
G1/S boundary. NIH3T3 cells (2 × 105) were seeded in 60 mm dish and
infected with either Ad-BTG2 virus (100 moi) or Ad-LacZ for 5 h. In 9 h,
the cells were treated with 2.5 mM thymidine for 12 h and then released
for 12 h by media change. Finally, the cells were harvested at the various
time points for FACS analysis to examine DNA content by staining with
propidium iodide. (B) NIH3T3 (2 × 105) cells synchronized by thymidine
treatment twice were harvested at 0, 4, 8 and 12 h and then subjected to
PI staining for FACS anlalysis. Note absence of any difference in the G2/M
phase progression between the Ad-BTG2 (100 moi) or Ad-LacZ infected
groups. (C) Quantification of each cell cycle phases observed in the
NIH3T3 cells infected with either Ad-BTG2 or Ad-LacZ virus along with
thymidine double block. No significant difference in the progression of
G2/M phase progression between the two groups. (D) Immunoblot
analysis showing the similar progression of G2/M phase, monitored by
cyclin B1 synthesis and degradation.
Additional file 4: Figure S4. HeLa cells (2 × 105) were seeded in
60 mm dish and maintained for 12 h. Cells were transfected with BTG2
cDNA (0.8 μg) and control vector (0.8 μg) for 6 h, followed by media
change. In 48 h, cells were harvested for immunoblot analysis to check
for upregulation of p21WAF1 protein induced by BTG2. α-tubulin was used
as a loading control.
Additional file 5: Primer sequences for RT-PCR, ChIP assay, and
gene cloning analyses in human cells.
Additional file 6: RNA sequences used for interference of BTG2
expression in human cells.
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